This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
MEI Pharma-Presage Biosciences on License Deal for Voruciclib
by Zacks Equity Research
MEI Pharma (MEIP) signs a license contract with Presage Biosciences to develop its CDK inhibitor, voruciclib, by dint of which, it nabs exclusive rights to the oncology candidate.
4 Drug Stocks Worth a Look on Promising Cancer Pipeline
by Zacks Equity Research
Cancer is the second most common cause of death in the U.S. preceded only by heart disease. We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
Incyte (INCY) Reports Positive Data on Epacadostat/Keytruda
by Zacks Equity Research
Incyte Corporation (INCY) announced new and updated data from the ongoing phase I/II ECHO-202 trial on pipeline candidate epacadostat with Keytruda.
Parkinson's Now a Hot Therapeutic Area: What's Up Lately?
by Zacks Equity Research
Parkinson's disease is a lucrative area due to lack of curative therapy in this space. Many players are trying to bring new treatments to the market. A lot has happened in last couple of months.
Roche's (RHHBY) Actemra Gets FDA Nod for Label Expansion
by Zacks Equity Research
Roche Holding AG's (RHHBY) drug Actemra got FDA approval for label expansion.
Immunogen Inks Deal With Jazz Pharma to Develop ADC Molecule
by Zacks Equity Research
ImmunoGen (IMGN) and Jazz Pharma announced a strategic collaboration to develop and commercialize antibody-drug conjugate products.
AstraZeneca and Takeda Ink Deal to Develop Parkinson's Drug
by Zacks Equity Research
AstraZeneca (AZN) and Takeda Pharmaceutical Company entered into an agreement to jointly develop and commercialize MEDI1341 for the potential treatment of Parkinson's disease.
Merck's CETP Inhibitor Reduces Cardiovascular Risk by 9%
by Zacks Equity Research
Detailed results from Merck's (MRK) REVEAL study on anacetrapib, showed that the CETP inhibitor and a statin reduced the risk of major coronary events by 9% relative to placebo.
Roche's Gazyva Gets Priority Review for Follicular Lymphoma
by Zacks Equity Research
Roche Holding AG (RHHBY) announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review to leukaemia drug Gazyva.
Novartis Announces Positive Data on Cardiovascular Drug
by Zacks Equity Research
Novartis AG (NVS) announced positive primary data on pipeline candidate canakinumab (ACZ885).
Foreign Stock Roundup: WPP 1H17, BHP Billiton Fiscal 2017 Results Impress
by Swarup Gupta
Foreign markets remained focused on the outcome of the annual economic symposium at Jackson Hole last week.
Sangamo Therapeutics Initiates Dosing in Hemophilia A Study
by Zacks Equity Research
Sangamo Therapeutics (SGMO) and partner Pfizer announced the dosing of first patient in Alta study on Hemophilia A candidate, SB-525.
Novartis (NVS) Receives EC Approval for Breast Cancer Drug
by Zacks Equity Research
Novartis AG (NVS) obtained approval for its breast cancer drug Kisqali in Europe.
Pharma Stock Roundup: Roche Drug Gets Priority Review, EU Nod for Novartis Drug
by Arpita Dutt
It was a pretty slow week with key highlights including regulatory updates from companies like Roche (RHHBY) and Novartis.
Celldex Ends Phase II Enrollment for Breast Cancer Candidate
by Zacks Equity Research
Celldex (CLDX) announces completion of enrollment in METRIC, a phase IIb study, evaluating glembatumumab vedotin for breast cancer treatment.
Roche (RHHBY) Hemophilia A Drug Granted Priority Review
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced that its Biologics License Application (BLA) for hemophilia A candidate, emicizumab has been accepted by the FDA and granted priority review.
BioLineRx Moves a Regulatory Submission for BL-8040 Trial
by Zacks Equity Research
BioLineRx (BLRX) forwards a regulatory submission to begin a phase III study to evaluate BL-8040 in combination with G-CSF for treatment of multiple myeloma.
Biogen & 6 Other Multiple Sclerosis Drug Stocks in Focus: Here's Why
by Arpita Dutt
Late last week, Biogen (BIIB) and six other pharma and biotech stocks were in the news due to the pricing of their multiple sclerosis ("MS") drugs.
Mylan Finalizes Settlement Agreement with DOJ for $465M
by Zacks Equity Research
Mylan N.V. (MYL) signed an agreement with the U.S. Department of Justice (DOJ) and two other relators to finalize the Medicaid drug rebate settlement worth $465 million, announced in Oct 2017.
Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx
by Zacks Equity Research
Exelixis, Inc. (EXEL) submitted its supplemental New Drug Application (sNDA) to the FDA for Cabometyx tablets for patients with previously untreated kidney cancer.
Ophthotech's Fovista Combo Regimen Disappoints in Phase III
by Zacks Equity Research
Ophthotech (OPHT) disappoints with poor evaluation of Fovista combined with Eylea or Avastin for treatment of AMD in phase III. The study misses the primary endpoint.
Bristol-Myers Opdivo Fails Kidney Cancer Trial CheckMate-214
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced disappointing top-line results from the CheckMate-214 trial on Opdivo in renal cell carcinoma.
Puma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus
by Zacks Equity Research
Puma Biotechnology (PBYI) reported narrower-than-expected loss in Q2. Shares were down in after-hours trading.
Mylan (MYL) Misses on Q2 Earnings & Sales, Lowers View
by Zacks Equity Research
Mylan N.V. (MYL) reported disappointing second-quarter 2017 results wherein both earnings and sales missed estimates. The company also lowered its guidance.
Inovio (INO) Q2 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Inovio Pharmaceuticals (INO) reports narrower-than-expected loss with revenue beating estimates. Moreover, the top line significantly increases year over year.